These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 8665548

  • 1. Effects of selegiline (deprenyl) on cognition in early Parkinson's disease.
    Dalrymple-Alford JC, Jamieson CF, Donaldson IM.
    Clin Neuropharmacol; 1995 Aug; 18(4):348-59. PubMed ID: 8665548
    [Abstract] [Full Text] [Related]

  • 2. The effect of deprenyl washout in patients with long-standing Parkinson's disease.
    Djaldetti R, Ziv I, Melamed E.
    J Neural Transm (Vienna); 2002 May; 109(5-6):797-803. PubMed ID: 12111469
    [Abstract] [Full Text] [Related]

  • 3. Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis.
    Giladi N, Asgharnejad M, Bauer L, Grieger F, Boroojerdi B.
    J Parkinsons Dis; 2016 Apr 02; 6(2):401-11. PubMed ID: 27061066
    [Abstract] [Full Text] [Related]

  • 4. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J, Kaakkola S, Ahtila S, Tuomainen P, Teräväinen H.
    Mov Disord; 1997 Jul 02; 12(4):497-505. PubMed ID: 9251066
    [Abstract] [Full Text] [Related]

  • 5. Selegiline and cognitive function in Parkinson's disease.
    Hietanen MH.
    Acta Neurol Scand; 1991 Nov 02; 84(5):407-10. PubMed ID: 1776388
    [Abstract] [Full Text] [Related]

  • 6. Selegiline (1-deprenyl) and low-dose levodopa treatment of Parkinson's disease. A double-blind crossover trial.
    Presthus J, Berstad J, Lien K.
    Acta Neurol Scand; 1987 Sep 02; 76(3):200-3. PubMed ID: 3120487
    [Abstract] [Full Text] [Related]

  • 7. An interim report of the effect of selegiline (L-deprenyl) on the progression of disability in early Parkinson's disease. The Parkinson Study Group.
    Shoulson I.
    Eur Neurol; 1992 Sep 02; 32 Suppl 1():46-53. PubMed ID: 1425820
    [Abstract] [Full Text] [Related]

  • 8. Selegiline as a primary treatment of Parkinson's disease.
    Myllylä VV, Sotaniemi KA, Vuorinen JA, Heinonen EH.
    Acta Neurol Scand Suppl; 1991 Sep 02; 136():70-2. PubMed ID: 1801540
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The relationship between depression and regional cerebral blood flow in Parkinson's disease and the effect of selegiline treatment.
    Imamura K, Okayasu N, Nagatsu T.
    Acta Neurol Scand; 2011 Jul 02; 124(1):28-39. PubMed ID: 20880269
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Delayed development of symptomatic improvement by (--)-deprenyl in Parkinson's disease.
    Mally J, Kovacs AB, Stone TW.
    J Neurol Sci; 1995 Dec 02; 134(1-2):143-5. PubMed ID: 8747857
    [Abstract] [Full Text] [Related]

  • 13. Symptomatic effect of selegiline in de novo Parkinsonian patients. The French Selegiline Multicenter Trial.
    Allain H, Pollak P, Neukirch HC.
    Mov Disord; 1993 Dec 02; 8 Suppl 1():S36-40. PubMed ID: 8302306
    [Abstract] [Full Text] [Related]

  • 14. A Randomized Double-Blind Placebo-Controlled Phase III Trial of Selegiline Monotherapy for Early Parkinson Disease.
    Mizuno Y, Hattori N, Kondo T, Nomoto M, Origasa H, Takahashi R, Yamamoto M, Yanagisawa N.
    Clin Neuropharmacol; 2017 Dec 02; 40(5):201-207. PubMed ID: 28857772
    [Abstract] [Full Text] [Related]

  • 15. Selegiline (L-deprenyl) and L-dopa treatment of Parkinson's disease: a double-blind trial.
    Takahashi M, Yuasa R, Imai T, Tachibana H, Yorifuji S, Nakamura Y, Ogawa N.
    Intern Med; 1994 Sep 02; 33(9):517-24. PubMed ID: 8000101
    [Abstract] [Full Text] [Related]

  • 16. L-deprenyl in Alzheimer's disease: cognitive and behavioral effects.
    Freedman M, Rewilak D, Xerri T, Cohen S, Gordon AS, Shandling M, Logan AG.
    Neurology; 1998 Mar 02; 50(3):660-8. PubMed ID: 9521253
    [Abstract] [Full Text] [Related]

  • 17. Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group.
    Pålhagen S, Heinonen EH, Hägglund J, Kaugesaar T, Kontants H, Mäki-Ikola O, Palm R, Turunen J.
    Neurology; 1998 Aug 02; 51(2):520-5. PubMed ID: 9710028
    [Abstract] [Full Text] [Related]

  • 18. Selegiline as initial treatment in de novo parkinsonian patients.
    Myllylä VV, Sotaniemi KA, Vuorinen JA, Heinonen EH.
    Neurology; 1992 Feb 02; 42(2):339-43. PubMed ID: 1736162
    [Abstract] [Full Text] [Related]

  • 19. Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group.
    Filip V, Kolibás E.
    J Psychiatry Neurosci; 1999 May 02; 24(3):234-43. PubMed ID: 10354658
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.